spacer
home > ebr > autumn 2018 > targeted technology
PUBLICATIONS
European Biopharmaceutical Review

Targeted Technology

By recognising the market value of a new class of bioelectronic medicine, which is based on biosensors, electronics, nanotechnology, and biotechnology research foundations, this article puts perspective forward on bringing the technology from lab to market. Here, a comprehensive review is provided on the progress and development of bioelectronic medicine in academia, clinical hospitals, and industrial settings.

‘Bioelectronics’ was first defined in 1991 as “the use of biological materials and biological architectures for information processing and new devices” (1). Furthermore, bioelectronics can be broadly elaborated as a fusion of electronics with biological systems where an electronic device facilitates in the transduction of signal from the biological systems to electrical device in the human body at a bioelectronic interface. R&D in bioelectronics has resulted in vital medical electronics devices, such as brain stimulators, glucose sensors, and pacemakers (2-4). This article will elaborate upon the current development of bioelectronics in academia and industry and, in addition, offer a future perspective with respect to the use of bioelectronic devices for precision medicine.

Bioelectronics in Precision Medicine

Interests in both clinical and fundamental research, with respect to personalised and precision medicine, are increasing. Personalised and precision medicine promises to revolutionise existing medical treatment. According to the Precision Medicine Initiative, precision medicine is defined as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.” Research has established a bioelectronic ecosystem consisting of portable biosensors and biomedical nano-robots that combine health monitoring with medical therapy (5). Such bioelectronic devices offer distinct advantages towards precision medicine.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deepak B Thimiri Govinda Raj holds a BTech in biotechnology from Bharathidasan University Trichy, India, and an ME in biotechnology from Birla Institute of Technology and Science, India. Deepak also has a PhD in biomedical sciences from KU Leuven, Belgium. Deepak is Co-Founder at DTCG® Consulting and Envirotransgene® Biosolutions Global. 

Prasanna Subramaniam has a BTech in biotechnology from Bharathidasan University Trichy, India, and an MTech in biopharmaceutical engineering and technology from Anna University, India. Prasanna has 12 years of experience in bioprocessing technology and biopharmaceutical operations. He is currently working as Deputy Manager at Biocon.

Dr Sri Saran Venkatachalam earned his BSc in applied sciences and MA of science in materials from Anna University, India. Sri also has a PhD in material science from the Institute of Electronics, Microelectronics, and Nanotechnology, France. He has 10 years of research and teaching experience in material science and electronics. Currently, he is an Assistant Professor at Bannari Amman Institute of Technology, India.

Dinh-Toi Chu PhD received a doctor of veterinary medicine degree at the Vietnam National University of Agriculture, Vietnam, an MA of biological science at the University of Ulsan, South Korea, and then a PhD in medicine at the Polish Academy of Sciences in Olsztyn and Medical University of Bialystok, Poland. Dinh-Toi has been a researcher and lecturer in immunology, cell biology, and animal pathology.
spacer
Dr Deepak B Thimiri Govinda Raj
spacer
spacer
spacer
Prasanna Subramaniam
spacer
spacer
spacer
Dr Sri Saran Venkatachalam
spacer
spacer
spacer
Dinh-Toi Chu PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement